Key points
- Johnson & Johnson reached a record price of $251.76 on June 26, 2026, achieving a total return of 65.12% over the 12-month period.
- Guggenheim raised its target from $266 to $270 while maintaining a Buy rating, naming JNJ as a leading large-cap biopharma company.
- Q2 2026 results expected July 15; Guggenheim expects revenue of $25.48 billion and earnings per share of $2.87, beating consensus estimates
- Strong prescription performance for Tremfya, Caplyta and Erleada supported the improved outlook
- The company faces a $32 million judgment in a mesothelioma lawsuit in Los Angeles
Johnson & Johnson shares rose to an unprecedented high of $251.76 on Thursday, June 26, before settling near $251.18, representing a decline of just 0.97% from that record level. This performance brings the pharma giant’s 12-month TSR to 65.12%, as it has a market valuation of $604.8 billion.
The rise coincided with Guggenheim’s announcement that it had raised its valuation target for JNJ to US$270 from US$266 previously, while reaffirming its buy recommendation. The investment firm has simultaneously highlighted JNJ as a prime option in the large-cap biopharmaceutical sector.
Guggenheim’s forecast for the second quarter of 2026 calls for revenue to reach $25.48 billion along with earnings per share of $2.87. These forecasts exceed the Street consensus, which calls for sales of $24.96 billion and earnings of $2.85 per share.
Motivating factors behind optimistic forecasts
The enhanced rating stems from better-than-expected prescription velocity data across three important drugs: Tremfya, Caplyta and Erleada. The performance metrics for each exceeded the Guggenheim’s own expectations.
Analysts note that tracking prescriptions for two recently introduced treatments — Ecotide and Enlexzo — is still too preliminary to be meaningfully integrated into models. These products will come under intense scrutiny as data sets become more comprehensive.
Guggenheim expects the July 15 earnings discussion to focus on Tremfya’s volume expansion, the commercial rollout of Icotyde, the company’s multiple myeloma pipeline, along with updates on Caplyta and Spravato.
JNJ The company boasts an impressive string of annual dividend increases over 55 years, enhancing its appeal among yield-oriented portfolio managers.
Institutional initiatives and challenges
Aside from market performance, JNJ It has unveiled plans to invest more than $1 billion in its facility in Jacksonville, Florida. These funds will support improved manufacturing, packaging and logistics infrastructure for the Vision sector, especially the production of ACUVUE contact lenses.
The organization also expanded domestic distribution of the TECNIS PureSee intraocular lens, designed for cataract procedures. On the research front, JNJ has revealed encouraging Phase 2/3 data for Imaavy in the treatment of patients with warm autoimmune hemolytic anemia.
However, legal headwinds remain. A Los Angeles jury decided JNJ was liable in Maria Lozano’s mesothelioma case, resulting in a $32 million verdict for her family. The ruling concerns allegations of asbestos contamination in the company’s baby powder products – a matter of long-standing judicial concern.
InvestingPro’s current assessment suggests shares may be trading at a premium to fundamental metrics, despite compelling upside momentum.
